NEW YORK, NY / ACCESSWIRE / September 10, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
CorMedix Inc. (NASDAQ:CRMD)
Investors Affected : July 8, 2020 - May 13, 2021
A class action has commenced on behalf of certain shareholders in CorMedix Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/cormedix-inc-loss-submission-form/?id=19485&from=1
Zymergen Inc. (NASDAQ:ZY)
This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.
A class action has commenced on behalf of certain shareholders in Zymergen Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/zymergen-inc-loss-submission-form/?id=19485&from=1
View, Inc. f/k/a CF Finance Acquisition Corp. II (NASDAQ:VIEW)
Investors Affected : November 30, 2020 - August 16, 2021
A class action has commenced on behalf of certain shareholders in View, Inc f/k/a CF Finance Acquisition Corp II. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) View had not properly accrued warranty costs related to its product; (2) there was a material weakness in View's internal controls over accounting and financial reporting related to warranty accrual; (3) as a result, the Company's financial results for prior periods were misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/view-inc-f-k-a-cf-finance-acquisition-corp-ii-loss-submission-form/?id=19485&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com:
https://www.accesswire.com/663536/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-CRMD-ZY-and-VIEW
